Use of the Markov model to estimate the waiting times in a modified WHO staging system for HIV infection.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Use of the Markov model to estimate the waiting times in a modified WHO staging system for HIV infection.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 15;8(5):474-9. Unique Identifier : AIDSLINE MED/95211540
Schechter MT; Le N; Craib KJ; Le TN; O'Shaughnessy MV; Montaner JS; B.C. Centre for Excellence in HIV/AIDS, St. Paul's Hospital,; Vancouver, Canada.

Abstract: Seroconverting men in the Vancouver Lymphadenopathy--Acquired Immune Deficiency Syndrome Study cohort were studied in this analysis to estimate the waiting times in the different stages of the modified World Health Organization (WHO) staging system for human immunodeficiency virus infection. A time-homogeneous staged Markov model was used, and it was assumed that infected individuals progress irreversibly from Stages I to IV and eventually to death. There were 130 individuals who seroconverted during the study (seroincident) and were included in this analysis. With use of the modified WHO staging system, the estimated mean waiting times for progression to Stage IV were 9.5, 6.5, and 2.0 years from stages I, II, and III, respectively. The estimated survival times were 11.2, 8.2, 3.7, and 1.7 years from Stages I to IV, respectively. Waiting times and survival were not significantly different when the lymphocyte count was used instead of the CD4 cell count in application of the staging system. The application of a staged Markov model to the modified WHO staging system suggests that this is a clinically sensible model. Furthermore, our results confirm that in the absence of CD4 cell counts, lymphocyte counts can be used as an alternative without substantial loss of information.

Keywords: Adult Cohort Studies CD4 Lymphocyte Count Disease Progression Follow-Up Studies Homosexuality, Male Human HIV Infections/*CLASSIFICATION/MORTALITY Likelihood Functions Lymphocyte Count Male Markov Chains Prognosis Support, Non-U.S. Gov't Survival Analysis Time Factors World Health Organization JOURNAL ARTICLE
950730
M9570909

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .